UroGen Capital Expenditures vs Depreciation Analysis

URGN Stock

USD 9.36 0.15 1.58%

UroGen Pharma financial indicator trend analysis is much more than just breaking down UroGen Pharma prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether UroGen Pharma is a good investment. Please check the relationship between UroGen Pharma Capital Expenditures and its Depreciation accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.

Capital Expenditures vs Depreciation

Capital Expenditures vs Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of UroGen Pharma Capital Expenditures account and Depreciation. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between UroGen Pharma's Capital Expenditures and Depreciation is 0.43. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of Depreciation in the same time period over historical financial statements of UroGen Pharma, assuming nothing else is changed. The correlation between historical values of UroGen Pharma's Capital Expenditures and Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of UroGen Pharma are associated (or correlated) with its Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation has no effect on the direction of Capital Expenditures i.e., UroGen Pharma's Capital Expenditures and Depreciation go up and down completely randomly.

Correlation Coefficient

0.43

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Capital Expenditures

Capital Expenditures are funds used by UroGen Pharma to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of UroGen Pharma operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Depreciation

Depreciation indicates how much of UroGen Pharma value has been used up. For tax purposes UroGen Pharma can deduct the cost of the tangible assets it purchases as business expenses. However, UroGen Pharma must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.

Most indicators from UroGen Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into UroGen Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.At this time, UroGen Pharma's Selling General Administrative is very stable compared to the past year. As of the 26th of February 2025, Tax Provision is likely to grow to about 1.2 M, while Issuance Of Capital Stock is likely to drop about 41.2 M.

UroGen Pharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Long Term Debt	Common Stock Total Equity	Short Term Investments	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Property Plant And Equipment Gross
Total Assets		0.93	0.96	-0.03	-0.16	0.82	-0.08	-0.87	0.8	0.86	0.61	0.93	0.87	0.78	0.95	0.78	0.99	0.96	0.69	0.92	0.91	0.78	0.75	0.74	0.88	0.9
Other Current Liab	0.93		0.99	-0.31	-0.43	0.76	0.08	-0.96	0.68	0.85	0.39	0.82	0.87	0.92	0.99	0.9	0.95	0.97	0.57	0.83	0.86	0.55	0.64	0.87	0.9	0.93
Total Current Liabilities	0.96	0.99		-0.28	-0.39	0.75	0.03	-0.96	0.77	0.89	0.38	0.86	0.89	0.92	1.0	0.89	0.98	0.99	0.56	0.88	0.9	0.63	0.7	0.87	0.9	0.91
Total Stockholder Equity	-0.03	-0.31	-0.28		0.99	0.18	-0.78	0.45	-0.01	-0.06	0.5	0.1	-0.14	-0.61	-0.27	-0.65	-0.12	-0.23	0.53	0.04	-0.03	0.43	0.13	-0.7	-0.13	-0.17
Net Tangible Assets	-0.16	-0.43	-0.39	0.99		0.12	-0.76	0.53	-0.1	-0.19	0.43	0.0	-0.23	-0.69	-0.39	-0.75	-0.25	-0.35	0.45	-0.06	-0.12	0.35	0.06	-0.78	-0.21	-0.31
Property Plant And Equipment Net	0.82	0.76	0.75	0.18	0.12		-0.21	-0.73	0.6	0.63	0.68	0.84	0.8	0.59	0.78	0.49	0.78	0.73	0.9	0.78	0.87	0.72	0.74	0.44	0.9	0.64
Net Debt	-0.08	0.08	0.03	-0.78	-0.76	-0.21		-0.18	-0.27	-0.31	-0.14	-0.24	-0.11	0.34	0.04	0.43	-0.06	-0.01	-0.49	-0.26	-0.19	-0.51	-0.33	0.48	-0.08	0.02
Retained Earnings	-0.87	-0.96	-0.96	0.45	0.53	-0.73	-0.18		-0.71	-0.78	-0.27	-0.79	-0.88	-0.97	-0.96	-0.93	-0.9	-0.93	-0.45	-0.8	-0.87	-0.49	-0.64	-0.91	-0.92	-0.82
Accounts Payable	0.8	0.68	0.77	-0.01	-0.1	0.6	-0.27	-0.71		0.82	0.31	0.89	0.84	0.62	0.74	0.6	0.83	0.8	0.43	0.88	0.87	0.84	0.85	0.57	0.78	0.58
Cash	0.86	0.85	0.89	-0.06	-0.19	0.63	-0.31	-0.78	0.82		0.25	0.83	0.82	0.71	0.87	0.7	0.9	0.9	0.55	0.87	0.83	0.72	0.73	0.66	0.77	0.82
Non Current Assets Total	0.61	0.39	0.38	0.5	0.43	0.68	-0.14	-0.27	0.31	0.25		0.6	0.42	0.12	0.41	0.14	0.49	0.38	0.77	0.43	0.47	0.64	0.39	0.1	0.47	0.48
Cash And Short Term Investments	0.93	0.82	0.86	0.1	0.0	0.84	-0.24	-0.79	0.89	0.83	0.6		0.93	0.65	0.85	0.63	0.92	0.88	0.72	0.92	0.96	0.85	0.86	0.58	0.91	0.77
Common Stock Shares Outstanding	0.87	0.87	0.89	-0.14	-0.23	0.8	-0.11	-0.88	0.84	0.82	0.42	0.93		0.79	0.89	0.74	0.89	0.88	0.61	0.83	0.92	0.66	0.84	0.7	0.94	0.77
Other Current Assets	0.78	0.92	0.92	-0.61	-0.69	0.59	0.34	-0.97	0.62	0.71	0.12	0.65	0.79		0.92	0.97	0.84	0.89	0.28	0.71	0.76	0.33	0.53	0.97	0.81	0.76
Other Stockholder Equity	0.95	0.99	1.0	-0.27	-0.39	0.78	0.04	-0.96	0.74	0.87	0.41	0.85	0.89	0.92		0.89	0.97	0.98	0.59	0.87	0.9	0.61	0.69	0.86	0.92	0.91
Total Liab	0.78	0.9	0.89	-0.65	-0.75	0.49	0.43	-0.93	0.6	0.7	0.14	0.63	0.74	0.97	0.89		0.83	0.87	0.18	0.67	0.69	0.31	0.47	1.0	0.73	0.79
Total Current Assets	0.99	0.95	0.98	-0.12	-0.25	0.78	-0.06	-0.9	0.83	0.9	0.49	0.92	0.89	0.84	0.97	0.83		0.99	0.63	0.94	0.92	0.74	0.76	0.79	0.89	0.9
Common Stock	0.96	0.97	0.99	-0.23	-0.35	0.73	-0.01	-0.93	0.8	0.9	0.38	0.88	0.88	0.89	0.98	0.87	0.99		0.56	0.92	0.91	0.66	0.72	0.84	0.88	0.91
Property Plant Equipment	0.69	0.57	0.56	0.53	0.45	0.9	-0.49	-0.45	0.43	0.55	0.77	0.72	0.61	0.28	0.59	0.18	0.63	0.56		0.65	0.69	0.72	0.62	0.13	0.69	0.58
Long Term Debt	0.92	0.83	0.88	0.04	-0.06	0.78	-0.26	-0.8	0.88	0.87	0.43	0.92	0.83	0.71	0.87	0.67	0.94	0.92	0.65		0.95	0.83	0.84	0.62	0.86	0.73
Common Stock Total Equity	0.91	0.86	0.9	-0.03	-0.12	0.87	-0.19	-0.87	0.87	0.83	0.47	0.96	0.92	0.76	0.9	0.69	0.92	0.91	0.69	0.95		0.79	0.84	0.65	0.97	0.73
Short Term Investments	0.78	0.55	0.63	0.43	0.35	0.72	-0.51	-0.49	0.84	0.72	0.64	0.85	0.66	0.33	0.61	0.31	0.74	0.66	0.72	0.83	0.79		0.74	0.26	0.68	0.51
Long Term Debt Total	0.75	0.64	0.7	0.13	0.06	0.74	-0.33	-0.64	0.85	0.73	0.39	0.86	0.84	0.53	0.69	0.47	0.76	0.72	0.62	0.84	0.84	0.74		0.43	0.77	0.55
Non Current Liabilities Total	0.74	0.87	0.87	-0.7	-0.78	0.44	0.48	-0.91	0.57	0.66	0.1	0.58	0.7	0.97	0.86	1.0	0.79	0.84	0.13	0.62	0.65	0.26	0.43		0.7	0.76
Capital Surpluse	0.88	0.9	0.9	-0.13	-0.21	0.9	-0.08	-0.92	0.78	0.77	0.47	0.91	0.94	0.81	0.92	0.73	0.89	0.88	0.69	0.86	0.97	0.68	0.77	0.7		0.75
Property Plant And Equipment Gross	0.9	0.93	0.91	-0.17	-0.31	0.64	0.02	-0.82	0.58	0.82	0.48	0.77	0.77	0.76	0.91	0.79	0.9	0.91	0.58	0.73	0.73	0.51	0.55	0.76	0.75

Click cells to compare fundamentals

UroGen Pharma Account Relationship Matchups

UroGen Pharma fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	122.0M	119.7M	136.2M	178.3M	205.1M	215.3M
Other Current Liab	18.2M	16.6M	17.4M	24.7M	28.4M	29.8M
Total Current Liabilities	21.4M	22.4M	23.9M	31.2M	35.9M	37.7M
Total Stockholder Equity	96.4M	8.4M	(88.7M)	(65.2M)	(58.7M)	(55.8M)
Net Tangible Assets	180.3M	96.4M	8.4M	(89.4M)	(102.8M)	(97.6M)
Property Plant And Equipment Net	4.2M	3.1M	3.7M	2.4M	2.7M	2.1M
Net Debt	(102.4M)	(44.0M)	43.7M	4.4M	4.0M	4.2M
Retained Earnings	(356.5M)	(467.3M)	(577.1M)	(679.3M)	(611.4M)	(580.8M)
Accounts Payable	3.3M	5.8M	5.5M	6.5M	7.5M	4.3M
Cash	103.9M	44.4M	55.4M	95.0M	109.3M	114.7M
Non Current Assets Total	6.4M	5.4M	6.7M	9.1M	10.5M	8.5M
Cash And Short Term Investments	103.9M	89.8M	100.0M	137.0M	157.5M	79.8M
Common Stock Shares Outstanding	21.8M	22.3M	22.8M	28.8M	33.2M	17.0M
Liabilities And Stockholders Equity	122.0M	119.7M	136.2M	178.3M	205.1M	215.3M
Other Current Assets	4.6M	8.7M	11.9M	11.1M	12.8M	13.4M
Other Stockholder Equity	452.5M	475.7M	487.8M	614.0M	706.1M	741.4M
Total Liab	25.7M	111.3M	225.0M	243.5M	280.1M	294.1M
Total Current Assets	115.6M	114.4M	128.9M	169.2M	194.6M	204.3M
Accumulated Other Comprehensive Income	271K	(25K)	(107K)	12K	13.8K	14.5K
Common Stock	60K	61K	63K	89K	102.4K	107.5K
Property Plant Equipment	4.7M	4.2M	2.0M	1.3M	1.5M	1.7M
Common Stock Total Equity	57K	60K	61K	63K	72.5K	45.9K
Short Term Investments	49.2M	44.8M	44.6M	42.0M	48.3M	43.2M
Non Current Liabilities Total	4.2M	89.0M	201.1M	212.3M	244.2M	256.4M
Capital Surpluse	408.0M	452.5M	475.7M	487.8M	561.0M	307.7M
Property Plant And Equipment Gross	4.2M	2.0M	1.3M	6.3M	7.3M	7.6M
Non Currrent Assets Other	289K	1.5M	2.7M	2.3M	2.6M	2.7M
Other Assets	487K	289K	29.9K	620K	713K	367.9K
Net Invested Capital	96.4M	8.4M	8.2M	33.3M	30.0M	55.5M
Net Working Capital	94.2M	92.0M	105.0M	138.0M	158.7M	112.3M
Retained Earnings Total Equity	(228.0M)	(356.5M)	(467.3M)	(577.1M)	(519.4M)	(545.4M)
Capital Stock	60K	61K	63K	89K	102.4K	68.6K
Short Long Term Debt Total	1.5M	398K	99.1M	100.2M	115.2M	121.0M
Capital Lease Obligations	1.5M	398K	1.6M	844K	759.6K	1.1M
Long Term Investments	1.9M	675K	0.0	4.5M	4.1M	3.8M

When determining whether UroGen Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of UroGen Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Urogen Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Urogen Pharma Stock:

How To Invest In UroGen

Details

Is UroGen Stock a good investment?

Details

What is UroGen Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.

You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.02)

Revenue Per Share

2.389

Quarterly Revenue Growth

0.209

Return On Assets

(0.21)

Return On Equity

(14.81)

The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

UroGen Capital Expenditures vs Depreciation Analysis

Capital Expenditures vs Depreciation

Capital Expenditures vs Depreciation Correlation Analysis

Correlation Coefficient

Capital Expenditures

Depreciation

UroGen Pharma fundamental ratios Correlations

UroGen Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

UroGen Pharma fundamental ratios Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Stockholder Equity	+ 1.0	Total Current Liabilities
Non Current Liabilities Total	+ 1.0	Total Liab
Total Current Assets	+ 0.99	Total Assets
Total Current Liabilities	+ 0.99	Other Current Liab
Other Stockholder Equity	+ 0.99	Other Current Liab
Common Stock	+ 0.99	Total Current Liabilities

Other Current Assets	- 0.97	Retained Earnings
Other Stockholder Equity	- 0.96	Retained Earnings
Retained Earnings	- 0.96	Total Current Liabilities
Retained Earnings	- 0.96	Other Current Liab
Common Stock	- 0.93	Retained Earnings
Total Liab	- 0.93	Retained Earnings